In vitro fluconazole and nystatin susceptibility and clinical outcome in complicated vulvovaginal candidosis

Mycoses

Volumn 54, Issue 6, 2011, Pages 501-505

  Fan, S R ^a   Liu, X P ^a  

^a PEKING UNIVERSITY SHENZHEN HOSPITAL   (China)

Author keywords

Fluconazole; Nystatin; Susceptibility; Treatment; Vulvovaginal candidosis

Indexed keywords

FLUCONAZOLE; NYSTATIN;

AGAR DIFFUSION; ARTICLE; CANDIDA ALBICANS; CANDIDA GLABRATA; CANDIDA TROPICALIS; DRUG SENSITIVITY; HUMAN; IN VITRO STUDY; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SACCHAROMYCES CEREVISIAE; TREATMENT OUTCOME; VAGINA CANDIDIASIS;

ADULT; ANTIFUNGAL AGENTS; CANDIDA; CANDIDIASIS, VULVOVAGINAL; DRUG RESISTANCE, FUNGAL; FEMALE; FLUCONAZOLE; HUMANS; MICROBIAL SENSITIVITY TESTS; NYSTATIN; TREATMENT OUTCOME;

CANDIDA; CANDIDA ALBICANS;

EID: 80053989457     PISSN: 09337407     EISSN: 14390507     Source Type: Journal    
DOI: 10.1111/j.1439-0507.2010.01887.x     Document Type: Article

References (27)

1. Sobel JD, Faro S, Force RW et al. Vulvovaginal candidiasis: epidemiologic, diagnostic, and therapeutic considerations. Am J Obstet Gynecol 1998; 178: 203-11.
2. Rex JH, Pfaller MA. Has antifungal susceptibility testing come of age? Clin Infect Dis 2002; 35: 982-9.
3. Arzeni D, Del Poeta M, Simonetti O et al. Prevalence and antifungal susceptibility of vaginal yeasts in outpatients attending a gynecological center in Ancona, Italy. Eur J Epidemiol 1997; 13: 447-50.
4. Ribeiro MA, Dietze R, Paula CR, Da Matta DA, Colombo AL. Susceptibility profile of vaginal yeast isolates from Brazil. Mycopathologia 2001; 151: 5-10.
5. Sobel JD, Zervos M, Reed BD et al. Fluconazole susceptibility of vaginal isolates obtained from women with complicated Candida vaginitis: clinical implications. Antimicrob Agents Chemother 2003; 47: 34-38.
6. Sojakova M, Liptajova D, Borovsky M, Subik J. Fluconazole and itraconazole susceptibility of vaginal yeast isolates from Slovakia. Mycopathologia 2004; 157: 163-9.
7. Richter SS, Galask RP, Messer SA, Hollis RJ, Diekema DJ, Pfaller MA. Antifungal susceptibilities of Candida species causing vulvovaginitis and epidemiology of recurrent cases. J Clin Microbiol 2005; 43: 2155-62.
8. Consolaro MEL, Albertoni TA, Svidzinski AE, Peralta RM, Svidzinski TIE. Vulvovaginal candidiasis is associated with the production of germ tubes by Candida albicans. Mycopathologia 2005; 159: 501-7.
9. Fan SR, Liu XP. In vitro miconazole susceptibility and clinical outcome in vulvovaginal candidiasis. Int J Gynaecol Obstet 2007; 97: 207-8.
10. Holland J, Young ML, Lee O, Chen SC-A. Vulvovaginal carriage of yeasts other than Candida albicans. Sex Transm Infect 2003; 79: 249-50.
11. Sobel JD, Chaim W, Nagappan V, Leaman D. Treatment of vaginitis caused by Candida glabrata: use of topical boric acid and flucytosine. Am J Obstet Gynecol 2003; 189: 1297-300.
12. Singh S, Sobel JD, Bhargava P, Boikov D, Vazquez JA. Vaginitis due to Candida krusei: epidemiology, clinical aspects, and therapy. Clin Infect Dis 2002; 35: 1066-70.
13. Fan SR, Liu XP. Nonalbicans Candida species and antifungal susceptibility. Int J Gynecol Obstet 2007; 98: 158-9.
14. CDC. Sexually transmitted diseases treatment guideline 2006. MMWR 2006; 55(RR-11): 54-55.
15. Rex JH, Pfaller MA, Galgiani JN et al. Development of interpretive breakpoints for antifungal susceptibility testing: conceptual framework and analysis of in vitro-in vivo correlation data for fluconazole, itraconazole, and Candida infections. Clin Infect Dis 1997; 24: 235-47.
16. Arikan S, Akova M, Hayran M et al. Correlation of in vitro fluconazole susceptibility with clinical outcome for severely ill patients with oropharyngeal candidiasis. Clin Infect Dis 1998; 26: 903-8.
17. Hernandez S, Lopez-Ribot JL, Najvar LK, McCarthy DI, Bocanegra R, Graybill JR. Casopfungin resistance in Candida albicans: correlating clinical outcome with laboratory susceptibility testing of three isogenic isolates serially obtained from a patient with progressive Candida esophagitis. Antimicrob Agents Chemother 2004; 48: 1382-3.
18. Pfaller MA, Diekema DJ, Rex JH et al. Correlation of MIC with outcome for Candida species tested against voriconazole: analysis and proposal for interpretive breakpoints. J Clin Microbiol 2007; 44: 819-26.
19. Walmsley S, King S, McGeer A, Ye Y, Richardson S. Oropharyngeal candidiasis in patients with human immunodeficiency virus: correlation of clinical outcome with in vitro resistance, serum azole levels, and immunosuppression. Clin Infect Dis 2001; 32: 1554-61.
20. Costa M, Passos XS, Miranda AT, de Araujo RS, Paula CR, Silva Mdo R. Correlation of in vitro itraconazole and fluconazole susceptibility with clinical outcome for patients with vulvovaginal candidiasis. Mycopathologia 2004; 157: 43-47.
21. Lynch ME, Sobel JD, Fidel PL Jr. Role of antifungal drug resistance in the pathogenesis of recurrent vulvovaginal candidiasis. J Med Vet Mycol 1996; 34: 337-9.
22. Rosco Diagnostica A/S. User's Guide for Neo-Sensitabs Susceptibility Testing, 18th edn. Taastrup, Denmark: Rosco Diagnostica A/S, 20052006.
23. Clinical and Laboratory Standards Institute/National Committee for Clinical Laboratory Standards. Method for Antifungal Disk Diffusion Susceptibility Testing of Yeasts: Approved Guideline. Document M44-A. Wayne, PA: Clinical and Laboratory Standards Institute, 2004.
24. McCutchan JA, Ronald AR, Corey L, Handsfield HH. Evaluation of new anti-infective drugs for the treatment of vaginal infections. Clin Infect Dis 1992; 15(Suppl. 1): 115-22.
25. American College of Obstetricians and Gynecologists (ACOG). ACOG Practice Bulletin No. 72. Vaginitis. Obstet Gynecol 2006; 107:1195-206.
26. National Committee for Clinical Laboratory Standards. Reference Method for Broth Dilution Antifungal Susceptibility Testing of Yeasts; Approved Standard. NCCLS Document M27-A2. Wayne, PA: National Committee for Clinical Laboratory Standards, 2002.
27. Shahid Z, Sobel JD. Reduced fluconazole susceptibility of Candida albicans isolates in women with recurrent vulvovaginal candidiasis: effects of long-term fluconazole therapy. Diagn Microbiol Infect Dis 2009; 64: 354-6.